Literature DB >> 12706688

Establishment of an analyzing method for a Japanese encephalitis virus neutralization test in Vero cells.

Motoharu Abe1, Syoji Kuzuhara, Yoichiro Kino.   

Abstract

We established a 50% plaque reduction analyzing method of neutralizing antibody for human serum to Japanese encephalitis virus (JEV) in Vero cells, called the '3 points least-squares regression method' (3LSRM). Our method shows a high correlation with the chick embryo cell method (the current standard method for human serum), using the chart method established by the National Institute of Infectious Diseases of Japan, which is an equation made with retrospective data obtained with the 50% plaque reduction method as a standard measurement method for neutralizing antibody titers to JEV. Our new method is much simpler and more reliable than the current method in that it uses an established cell line, Vero cells, and its results are computed by the 3LSRM.

Entities:  

Mesh:

Year:  2003        PMID: 12706688     DOI: 10.1016/s0264-410x(02)00772-7

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Phase III clinical trials comparing the immunogenicity and safety of the vero cell-derived Japanese encephalitis vaccine Encevac with those of mouse brain-derived vaccine by using the Beijing-1 strain.

Authors:  Chiaki Miyazaki; Kenji Okada; Takao Ozaki; Mizuo Hirose; Kaneshige Iribe; Hiroyuki Yokote; Yuji Ishikawa; Takehiro Togashi; Kohji Ueda
Journal:  Clin Vaccine Immunol       Date:  2013-12-11

2.  Obesity-induced chronic inflammation is associated with the reduced efficacy of influenza vaccine.

Authors:  Hye-Lim Park; Seung-Hyun Shim; Eun-Young Lee; Whajung Cho; Sooho Park; Hyun-Jung Jeon; Sun-Young Ahn; Hun Kim; Jae-Hwan Nam
Journal:  Hum Vaccin Immunother       Date:  2014-03-10       Impact factor: 3.452

3.  Safety and immunogenicity of a freeze-dried, Vero cell culture-derived, inactivated Japanese encephalitis vaccine (KD-287, ENCEVAC®) versus a mouse brain-derived inactivated Japanese encephalitis vaccine in children: a phase III, multicenter, double-blinded, randomized trial.

Authors:  Ki Wook Yun; Hoan Jong Lee; Jin Han Kang; Byung Wook Eun; Yae-Jean Kim; Kyung-Hyo Kim; Nam Hee Kim; Young Jin Hong; Dong Ho Kim; Hwang Min Kim; Sung-Ho Cha
Journal:  BMC Infect Dis       Date:  2015-01-08       Impact factor: 3.090

4.  Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine.

Authors:  Ede Qin; Huiying Shi; Lin Tang; Cuie Wang; Guohui Chang; Zhifen Ding; Kai Zhao; Jian Wang; Ze Chen; Man Yu; Bingyin Si; Jianyuan Liu; Donglai Wu; Xiaojie Cheng; Baoan Yang; Wenming Peng; Qingwen Meng; Bohua Liu; Weiguo Han; Xunnan Yin; Hongyuan Duan; Dawei Zhan; Long Tian; Shuangli Li; Jinsong Wu; Gang Tan; Yi Li; Yuchuan Li; Yonggang Liu; Hong Liu; Fushuang Lv; Yu Zhang; Xiangang Kong; Baochang Fan; Tao Jiang; Shuli Xu; Xiaomei Wang; Changwen Li; Xiaohong Wu; Yongqiang Deng; Min Zhao; Qingyu Zhu
Journal:  Vaccine       Date:  2005-09-12       Impact factor: 3.641

5.  Comparison of JEV neutralization assay using pseudotyped JEV with the conventional plaque-reduction neutralization test.

Authors:  Hee-Jung Lee; Kyung-Il Min; Ki Hoon Park; Hyo Jung Choi; Min-Kyoung Kim; Chi-Young Ahn; Young-Jin Hong; Young Bong Kim
Journal:  J Microbiol       Date:  2014-03-07       Impact factor: 3.422

6.  Persistence of Immune Responses With an Inactivated Japanese Encephalitis Single-Dose Vaccine, JENVAC and Interchangeability With a Live-Attenuated Vaccine.

Authors:  Krishna Mohan Vadrevu; Venugopal Potula; Vasant Khalatkar; Niranjana S Mahantshetty; Atish Shah; Raches Ella
Journal:  J Infect Dis       Date:  2020-10-01       Impact factor: 5.226

7.  Prevalence of Neutralizing Antibodies to Japanese Encephalitis Virus among High-Risk Age Groups in South Korea, 2010.

Authors:  Eun Ju Lee; Go-Woon Cha; Young Ran Ju; Myung Guk Han; Won-Ja Lee; Young Eui Jeong
Journal:  PLoS One       Date:  2016-01-25       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.